These preliminary data suggest that adding TIM-3 blockade to PD-1 inhibition could represent a promising approach to enhance responses in NSCLC patients refractory to standard immunotherapy, supporting further investigation in selected cohorts or in combination with other agents [57]. The gene discussed is HAVCR2; the disease is non-small cell lung carcinoma.